DK1753723T3 - Substituerede quinolinderivater som mitotiske kinesininhibitorer - Google Patents

Substituerede quinolinderivater som mitotiske kinesininhibitorer

Info

Publication number
DK1753723T3
DK1753723T3 DK05752901T DK05752901T DK1753723T3 DK 1753723 T3 DK1753723 T3 DK 1753723T3 DK 05752901 T DK05752901 T DK 05752901T DK 05752901 T DK05752901 T DK 05752901T DK 1753723 T3 DK1753723 T3 DK 1753723T3
Authority
DK
Denmark
Prior art keywords
substituted quinoline
quinoline derivatives
mitotic kinesin
kinesin inhibitors
compounds
Prior art date
Application number
DK05752901T
Other languages
Danish (da)
English (en)
Inventor
W Wang
R Constantine
L Lagniton
K Bair
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1753723T3 publication Critical patent/DK1753723T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK05752901T 2004-05-21 2005-05-19 Substituerede quinolinderivater som mitotiske kinesininhibitorer DK1753723T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57312004P 2004-05-21 2004-05-21
PCT/US2005/017961 WO2005113507A1 (fr) 2004-05-21 2005-05-19 Dérivés de quinolinone substituée en tant qu’inhibiteurs de kinésine mitotique

Publications (1)

Publication Number Publication Date
DK1753723T3 true DK1753723T3 (da) 2008-10-20

Family

ID=34970815

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05752901T DK1753723T3 (da) 2004-05-21 2005-05-19 Substituerede quinolinderivater som mitotiske kinesininhibitorer

Country Status (19)

Country Link
US (2) US7452996B2 (fr)
EP (1) EP1753723B1 (fr)
JP (1) JP2008502721A (fr)
CN (1) CN1956960A (fr)
AT (1) ATE404536T1 (fr)
AU (1) AU2005245492A1 (fr)
BR (1) BRPI0511433A (fr)
CA (1) CA2564215A1 (fr)
DE (1) DE602005008953D1 (fr)
DK (1) DK1753723T3 (fr)
ES (1) ES2311992T3 (fr)
HR (1) HRP20080493T3 (fr)
MX (1) MXPA06011958A (fr)
PL (1) PL1753723T3 (fr)
PT (1) PT1753723E (fr)
RS (1) RS50670B (fr)
RU (1) RU2385867C2 (fr)
SI (1) SI1753723T1 (fr)
WO (1) WO2005113507A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1753723E (pt) * 2004-05-21 2008-11-19 Novartis Vaccines & Diagnostic Derivados de quinolina substituída como inibidores de quinesina mitótica
CA2575188A1 (fr) 2004-08-18 2006-02-23 Astrazeneca Ab Enantiomeres de pyrimidones fusionnes selectionnes et utilisations dans le traitement et la prevention du cancer
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8202837B2 (en) * 2005-11-04 2012-06-19 Glaxosmithkline Llc Methods for administering hypoglycemic agents
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
KR20090081020A (ko) * 2006-11-13 2009-07-27 노파르티스 아게 Ｋｓｐ 억제제로서의 치환된 피라졸 및 트리아졸 화합물
CA2674318A1 (fr) * 2007-01-05 2008-07-17 Novartis Ag Derives cyclises en tant qu'inhibiteurs d'eg-5
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
JP2013525290A (ja) * 2010-04-15 2013-06-20 ノバルティス アーゲー Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物
CA2794406A1 (fr) * 2010-04-15 2011-10-20 Novartis Ag Composes de triazole comme inhibiteurs de la ksp
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
CA2881937A1 (fr) * 2012-08-13 2014-02-20 Array Biopharma Inc. Arry-520 destine a etre utilise dans le traitement du cancer chez un patient ayant un faible taux de aag
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
KR20180037953A (ko) * 2015-08-19 2018-04-13 에자이 알앤드디 매니지먼트 가부시키가이샤 담관암을 위한 치료제

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172087B1 (en) * 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
AU4055400A (en) 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CA2425185A1 (fr) 2000-10-06 2002-04-11 Stephane De Lombaert Derives de benzimidazole et d'indole en tant que modulateurs des recepteurs de la corticoliberine
HUP0500880A2 (en) 2000-12-11 2006-05-29 Tularik Inc Cxcr3 antagonists and pharmaceutical compositions thereof
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
WO2002056880A1 (fr) 2001-01-19 2002-07-25 Cytokinetics, Inc. Inhibiteurs triphenylmethane de la kinesine
US7060705B2 (en) 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (fr) 2001-11-20 2003-05-30 Cytokinetics, Inc. Procede de racemisation de quinazolinones chirales
CA2467916A1 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs miotitiques de la kinesine
AU2002364128B2 (en) 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2468156A1 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
JP2005526709A (ja) 2002-01-10 2005-09-08 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換ベンゾイミダゾールアナログ
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
JP4399269B2 (ja) 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
US6924376B2 (en) 2002-04-17 2005-08-02 Cytokinetics, Inc. Compounds, compositions and methods
CA2485148A1 (fr) 2002-05-09 2003-11-20 Cytokinetics, Inc. Composes, compositions et procedes
WO2003097053A1 (fr) 2002-05-09 2003-11-27 Cytokinetics, Inc. Composes, compositions et procedes
WO2003103575A2 (fr) 2002-05-23 2003-12-18 Cytokinetics, Inc. Composes, compositions et procedes
CA2483627A1 (fr) 2002-05-23 2003-12-04 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
ATE446094T1 (de) 2002-06-14 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
WO2003106417A1 (fr) 2002-06-14 2003-12-24 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
EP1556357A4 (fr) 2002-06-14 2006-09-13 Cytokinetics Inc Composes, compositions et procedes
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
US6949538B2 (en) 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
PT1753723E (pt) * 2004-05-21 2008-11-19 Novartis Vaccines & Diagnostic Derivados de quinolina substituída como inibidores de quinesina mitótica

Also Published As

Publication number Publication date
ATE404536T1 (de) 2008-08-15
PT1753723E (pt) 2008-11-19
RU2006145336A (ru) 2008-06-27
WO2005113507A1 (fr) 2005-12-01
RU2385867C2 (ru) 2010-04-10
ES2311992T3 (es) 2009-02-16
MXPA06011958A (es) 2006-12-15
EP1753723A1 (fr) 2007-02-21
AU2005245492A1 (en) 2005-12-01
CN1956960A (zh) 2007-05-02
US20090028858A1 (en) 2009-01-29
DE602005008953D1 (de) 2008-09-25
PL1753723T3 (pl) 2009-01-30
JP2008502721A (ja) 2008-01-31
BRPI0511433A (pt) 2007-12-11
HRP20080493T3 (en) 2009-02-28
EP1753723B1 (fr) 2008-08-13
CA2564215A1 (fr) 2005-12-01
US20050261337A1 (en) 2005-11-24
RS50670B (sr) 2010-06-30
US7452996B2 (en) 2008-11-18
SI1753723T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
TW200612958A (en) Substituted imidazole derivatives
MX2007004699A (es) Derivados de indol y bencimidazol.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
WO2008086122A3 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
ME01992B (fr) Composes diarylhydantoines
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TW200728307A (en) Novel spirochromanone derivatives
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
WO2011058474A8 (fr) Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
MX2012003982A (es) Pirrolidinas n-substituidas.
UA97256C2 (ru) Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
PA8821301A1 (es) Inhibidores a base de hidroxamato de desacetilasas b
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2007017728A3 (fr) Nouveaux composes heterocycliques
TW200738651A (en) Cyclohexyl sulfonamide derivatives
WO2007000655A3 (fr) Nouveaux dérivés de pyrazolopyrimidinone
RS54693B1 (en) SULFONAMIDES FOR THE PREVENTION OF DIABETES